Equities research analysts expect Teleflex Incorporated (NYSE:TFX) to post $2.39 earnings per share for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for Teleflex’s earnings. The highest EPS estimate is $2.42 and the lowest is $2.37. Teleflex reported earnings of $2.13 per share in the same quarter last year, which would suggest a positive year over year growth rate of 12.2%. The business is expected to announce its next quarterly earnings report on Thursday, February 22nd.

On average, analysts expect that Teleflex will report full-year earnings of $8.34 per share for the current financial year, with EPS estimates ranging from $8.26 to $8.38. For the next financial year, analysts expect that the business will report earnings of $9.67 per share, with EPS estimates ranging from $9.54 to $9.85. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover Teleflex.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, beating the consensus estimate of $2.01 by $0.11. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The firm had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. During the same quarter last year, the firm posted $1.80 EPS. The company’s revenue was up 17.3% compared to the same quarter last year.

Several analysts have weighed in on TFX shares. Zacks Investment Research raised Teleflex from a “hold” rating to a “buy” rating and set a $261.00 price target on the stock in a report on Tuesday, September 12th. Barclays reaffirmed an “overweight” rating and issued a $253.00 price target (up previously from $230.00) on shares of Teleflex in a report on Tuesday, September 12th. Deutsche Bank reaffirmed a “buy” rating and issued a $251.00 price target (up previously from $238.00) on shares of Teleflex in a report on Monday, September 18th. Stephens reaffirmed a “buy” rating and issued a $270.00 price target (up previously from $230.00) on shares of Teleflex in a report on Monday, September 25th. Finally, Needham & Company LLC raised their price target on Teleflex from $228.00 to $237.00 and gave the company a “buy” rating in a report on Tuesday, September 5th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company’s stock. Teleflex currently has a consensus rating of “Hold” and a consensus target price of $274.44.

In related news, Director Stephen K. M.D. Klasko sold 200 shares of the firm’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $237.18, for a total transaction of $47,436.00. Following the transaction, the director now directly owns 8,080 shares in the company, valued at approximately $1,916,414.40. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Benson Smith sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $258.10, for a total value of $516,200.00. Following the transaction, the chief executive officer now owns 76,634 shares in the company, valued at $19,779,235.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,600 shares of company stock worth $665,076. 2.39% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Toronto Dominion Bank grew its position in Teleflex by 14.5% during the 2nd quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 70 shares during the last quarter. Advisory Services Network LLC grew its position in Teleflex by 933.8% during the 2nd quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock worth $172,000 after acquiring an additional 747 shares during the last quarter. Cornerstone Capital Management Holdings LLC. bought a new position in Teleflex during the 2nd quarter worth approximately $175,000. Calamos Advisors LLC bought a new position in Teleflex during the 2nd quarter worth approximately $206,000. Finally, Archford Capital Strategies LLC grew its position in Teleflex by 29,025.0% during the 2nd quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock worth $217,000 after acquiring an additional 1,161 shares during the last quarter. Institutional investors and hedge funds own 89.31% of the company’s stock.

Teleflex (NYSE TFX) traded down $2.32 during trading hours on Wednesday, hitting $249.86. The company’s stock had a trading volume of 392,100 shares, compared to its average volume of 262,536. Teleflex has a 1 year low of $154.77 and a 1 year high of $271.23. The stock has a market cap of $11,360.52, a PE ratio of 31.17, a P/E/G ratio of 2.16 and a beta of 1.09. The company has a current ratio of 4.72, a quick ratio of 3.70 and a debt-to-equity ratio of 0.88.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 15th. Investors of record on Wednesday, November 15th will be issued a dividend of $0.34 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $1.36 dividend on an annualized basis and a dividend yield of 0.54%. Teleflex’s dividend payout ratio is 24.82%.

ILLEGAL ACTIVITY NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The correct version of this article can be read at https://www.americanbankingnews.com/2017/12/13/teleflex-incorporated-tfx-expected-to-announce-earnings-of-2-39-per-share-2.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with MarketBeat.com's FREE daily email newsletter.